

Xiubao Ren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1336863/publications.pdf>

Version: 2024-02-01

126
papers

6,603
citations

101496

36
h-index

71651

76
g-index

131
all docs

131
docs citations

131
times ranked

10602
citing authors

#	ARTICLE	IF	CITATIONS
1	Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. <i>British Journal of Haematology</i> , 2022, 196, 617-628.	1.2	7
2	Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
3	Somatic copy number alteration predicts clinical benefit of lung adenocarcinoma patients treated with cytokine-induced killer plus chemotherapy. <i>Cancer Gene Therapy</i> , 2022, 29, 1153-1159.	2.2	3
4	A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2022, 166, 98-106.	0.9	1
5	Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001). <i>Annals of Translational Medicine</i> . 2022. 10. 229-229.	0.7	25
6	Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002). <i>Frontiers in Oncology</i> , 2022, 12, 831345.	1.3	18
7	Downregulation of PD-L1 and HLA in non-small cell lung cancer with ALK fusion. <i>Thoracic Cancer</i> , 2022, 13, 1153-1163.	0.8	5
8	A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 343-355.	0.8	2
9	Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL. <i>Frontiers in Immunology</i> , 2022, 10, e004114.		16
10	PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma. <i>Clinical and Translational Medicine</i> , 2022, 12, e808.	1.7	7
11	CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. <i>Cell Death and Disease</i> , 2022, 13, 441.	2.7	18
12	Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer. <i>Journal of Leukocyte Biology</i> , 2022, 112, 1591-1603.	1.5	5
13	Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. <i>BioMed Research International</i> , 2022, 2022, 1-18.	0.9	1
14	Trained Immunity of IL-12-, IL-15-, and IL-18-Induced CD3+CD56+ NKT-Like Cells. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	1
15	Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC). <i>Cell Death and Disease</i> , 2022, 13, .	2.7	20
16	Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-L1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study. <i>Thoracic Cancer</i> , 2021, 12, 145-152.	0.8	12
17	Morphine-3-glucuronide upregulates PD-L1 expression and promotes the immune escape of non-small cell lung cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 155-171.	1.4	16
18	Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer. <i>Translational Oncology</i> , 2021, 14, 101004.	1.7	12

#	ARTICLE	IF	CITATIONS
19	Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and in vitro Expanded iTregs. <i>Frontiers in Immunology</i> , 2021, 12, 619932.	2.2	9
20	Lung cancer-associated mesenchymal stem cells promote tumor metastasis and tumorigenesis by induction of epithelialâ€mesenchymal transition and stem-like reprogram. <i>Aging</i> , 2021, 13, 9780-9800.	1.4	11
21	Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large Bâ€cell lymphoma in the rituximab era. <i>Hematological Oncology</i> , 2021, 39, 490-497.	0.8	2
22	Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2193-2204.	1.3	16
23	Identification of Key Genes With Differential Correlations in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 675438.	1.8	14
24	Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1â™PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-ÎB axis in breast cancer. <i>Cell Death and Disease</i> , 2021, 12, 465.	2.7	25
25	TIM-3 and CEACAM1 are Prognostic Factors in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 619765.	1.6	15
26	An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 708784.	1.3	3
27	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2109-2120.	0.5	75
28	Bortezomib enhances the anti-cancer effect of the novel Brutonâ€™s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. <i>Aging</i> , 2021, 13, 21102-21121.	1.4	3
29	Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 103-114.	0.7	3
30	The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	2
31	Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	2
32	Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	3
33	High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. <i>Frontiers in Immunology</i> , 2021, 12, 779248.	2.2	3
34	The Distinct Impact of TAM Infiltration on the Prognosis of Patients With Cardia and Non-Cardia Gastric Cancer and Its Association With <i>H. pylori</i> Infection. <i>Frontiers in Oncology</i> , 2021, 11, 737061.	1.3	4
35	EZH2 identifies the precursors of human natural killer cells with trained immunity. <i>Cancer Biology and Medicine</i> , 2021, 18, 1021-1039.	1.4	5
36	The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancerâ€™A Phase II Study. <i>Frontiers in Immunology</i> , 2021, 12, 772450.	2.2	42

#	ARTICLE	IF	CITATIONS
37	New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1127-1136.	3.3	59
38	Significantly different immunological score in lung adenocarcinoma and squamous cell carcinoma and a proposal for a new immune staging system. <i>OncolImmunology</i> , 2020, 9, 1828538.	2.1	20
39	Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 244.	7.1	10
40	Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 153093.	1.0	9
41	Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 761-767.	1.3	7
42	Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-9.	0.9	12
43	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) Tj ETQq1 1 0.784314288 / Over	1.0	14
44	Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. <i>Journal of Cancer</i> , 2020, 11, 7001-7008.	1.2	17
45	Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis. <i>OncolImmunology</i> , 2020, 9, 1807291.	2.1	63
46	Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. <i>Frontiers in Oncology</i> , 2020, 10, 664.	1.3	19
47	Primary tumor standardized uptake value (SUVmax) measured on 18F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2595-2605.	1.2	3
48	Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment. <i>Thoracic Cancer</i> , 2020, 11, 1170-1179.	0.8	16
49	Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 562-570.	2.0	36
50	Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer. <i>International Immunopharmacology</i> , 2020, 84, 106506.	1.7	12
51	An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090542.	1.4	15
52	Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. <i>Cancer Biology and Medicine</i> , 2020, 17, 626-639.	1.4	7
53	Exhausted T cells and epigenetic status. <i>Cancer Biology and Medicine</i> , 2020, 17, 923-936.	1.4	32
54	Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study. <i>Translational Lung Cancer Research</i> , 2020, 9, 2401-2410.	1.3	2

#	ARTICLE	IF	CITATIONS
55	Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. <i>Cancer Biology and Medicine</i> , 2019, 16, 205.	1.4	40
56	Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome. <i>International Journal of Cancer</i> , 2019, 145, 1414-1422.	2.3	24
57	Clinical Significance of Serum Type III Interferons in Patients with Gastric Cancer. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 155-163.	0.5	5
58	T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. <i>Cell Death and Disease</i> , 2019, 10, 475.	2.7	16
59	Nicotine promotes the development of non-small cell lung cancer through activating LINC00460 and PI3K/Akt signaling. <i>Bioscience Reports</i> , 2019, 39, .	1.1	21
60	Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 439.	1.3	13
61	Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting <i>ONECUT2</i> . <i>Cancer Research</i> , 2019, 79, 3608-3621.	0.4	129
62	Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. <i>Hematological Oncology</i> , 2019, 37, 270-276.	0.8	18
63	Chemoradiotherapy-Induced CD4+ and CD8+ T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 73.	1.3	17
64	Memory stem T cells generated by Wnt signaling from blood of human renal clear cell carcinoma patients. <i>Cancer Biology and Medicine</i> , 2019, 16, 109.	1.4	15
65	Nociceptin Receptor Is Overexpressed in Non-small Cell Lung Cancer and Predicts Poor Prognosis. <i>Frontiers in Oncology</i> , 2019, 9, 235.	1.3	9
66	A new perspective: Exploring future therapeutic strategies for cancer by understanding the dual role of B lymphocytes in tumor immunity. <i>International Journal of Cancer</i> , 2019, 144, 2909-2917.	2.3	24
67	Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2019, 134, 5231-5231.	0.6	0
68	Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. <i>Clinical Cancer Research</i> , 2018, 24, 2370-2382.	3.2	39
69	Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. <i>Nature Cell Biology</i> , 2018, 20, 597-609.	4.6	306
70	Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2018, 25, 1160-1173.	5.0	51
71	A novel MDSC-induced PD-1 ^{hi} PD-L1 ⁺ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties. <i>Oncolmmunology</i> , 2018, 7, e1413520.	2.1	61
72	PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection. <i>Frontiers in Oncology</i> , 2018, 8, 604.	1.3	15

#	ARTICLE	IF	CITATIONS
73	Inhibitory effect of <i>Dendrobium officinale</i> polysaccharide on human gastric cancer cell xenografts in nude mice. <i>Food Science and Technology</i> , 2018, 38, 78-83.	0.8	13
74	New insights into the biological impacts of immune cell-derived exosomes within the tumor environment. <i>Cancer Letters</i> , 2018, 431, 115-122.	3.2	55
75	Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e381-e389.	0.2	14
76	Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2018, 21, 150.	0.8	12
77	New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms. <i>Frontiers in Immunology</i> , 2018, 9, 470.	2.2	84
78	Prospective, multicenter, noninterventional and registry clinical study of apatinib in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 137-137.	0.8	1
79	Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet. <i>Tumor Biology</i> , 2017, 39, 101042831770163.	0.8	8
80	Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway. <i>Molecular Immunology</i> , 2017, 81, 102-107.	1.0	11
81	Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells. <i>Frontiers in Immunology</i> , 2017, 8, 404.	2.2	73
82	Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy. <i>Frontiers in Immunology</i> , 2017, 8, 456.	2.2	51
83	Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2. <i>Frontiers in Immunology</i> , 2017, 8, 1426.	2.2	17
84	Interleukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1840.	2.2	92
85	Cytokine-Induced Killer Cells Modulates Resistance to Cisplatin in the A549/DDP Cell Line. <i>Journal of Cancer</i> , 2017, 8, 3287-3295.	1.2	16
86	Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis. <i>PLoS ONE</i> , 2017, 12, e0166014.	1.1	4
87	The role of toll-like receptor 4 in tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 66656-66667.	0.8	71
88	Efficacy of ALK5 inhibition in myelofibrosis. <i>JCI Insight</i> , 2017, 2, e90932.	2.3	37
89	Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors. <i>Oncotarget</i> , 2017, 8, 68746-68757.	0.8	6
90	Anti-PD-1 monoclonal antibody combined CD3-retronectin activated T cell in heavy-treated renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3047-3047.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1718.	1.8	22
92	Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial. <i>Clinical Colorectal Cancer</i> , 2016, 15, 228-235.	1.0	38
93	A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. <i>Blood</i> , 2016, 128, 249-252.	0.6	58
94	Adoptive Cellular Therapy (ACT) for Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 169-239.	0.8	14
95	IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review). <i>International Journal of Oncology</i> , 2016, 48, 5-12.	1.4	122
96	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4119-4132.	3.2	266
97	Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects. <i>Tumor Biology</i> , 2016, 37, 8425-8435.	0.8	28
98	Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF- κ B and ERK5 signaling pathway. <i>Biochemical Pharmacology</i> , 2016, 99, 132-145.	2.0	21
99	Positive and negative functions of B lymphocytes in tumors. <i>Oncotarget</i> , 2016, 7, 55828-55839.	0.8	46
100	Plasma miR-324-3p and miR-1285 as diagnostic and prognostic biomarkers for early stage lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 59664-59675.	0.8	45
101	BMP signaling and its paradoxical effects in tumorigenesis and dissemination. <i>Oncotarget</i> , 2016, 7, 78206-78218.	0.8	70
102	Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 26070-26086.	0.8	52
103	Soluble Toll-like receptor 4 is a potential serum biomarker in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 40106-40114.	0.8	31
104	Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. <i>Oncotarget</i> , 2016, 7, 43604-43615.	0.8	45
105	PD-L1 expression and its significance in Chinese patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20013-e20013.	0.8	0
106	Role of microRNA-150 in solid tumors. <i>Oncology Letters</i> , 2015, 10, 11-16.	0.8	50
107	Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells. <i>Frontiers in Immunology</i> , 2015, 6, 633.	2.2	12
108	The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications. <i>Oncotarget</i> , 2015, 6, 42590-42602.	0.8	37

#	ARTICLE	IF	CITATIONS
109	Digital Karyotyping with Whole Genomic Sequencing for Complex Congenital Disorder. <i>Journal of Genetics and Genomics</i> , 2015, 42, 651-655.	1.7	1
110	Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. <i>Nature Cell Biology</i> , 2015, 17, 183-194.	4.6	895
111	Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer. <i>Cancer Genetics</i> , 2015, 208, 76-84.	0.2	24
112	High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer. <i>Tumor Biology</i> , 2015, 36, 9405-9410.	0.8	12
113	Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 2586-2594.	1.4	211
114	Regulatory B cell: New member of immunosuppressive cell club. <i>Human Immunology</i> , 2015, 76, 615-621.	1.2	37
115	Apurinic/Apyrimidinic Endonuclease 1 Induced Genomic Instability Causes T-Cell Acute Lymphoblastic Leukemia in Zebrafish. <i>Blood</i> , 2015, 126, 1431-1431.	0.6	0
116	Mesenchymal Cell Associated Fibrosis in Experimental mPlW515L Mouse Model of Myelofibrosis. <i>Blood</i> , 2015, 126, 604-604.	0.6	7
117	Noncanonical NF- κ B Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer. <i>Journal of Immunology</i> , 2014, 193, 2574-2586.	0.4	181
118	TGF β 2 Induces BRCAness and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes. <i>Molecular Cancer Research</i> , 2014, 12, 1597-1609.	1.5	56
119	Can the dual-functional capability of CIK cells be used to improve antitumor effects?. <i>Cellular Immunology</i> , 2014, 287, 18-22.	1.4	27
120	Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis. <i>Cancer Cell</i> , 2014, 25, 501-515.	7.7	1,198
121	Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF- κ B. <i>Scientific Reports</i> , 2014, 4, 5750.	1.6	270
122	Cancer immunoinformatics: a new assistant tool for malignant disease research. <i>Chinese Medical Journal</i> , 2014, 127, 1149-54.	0.9	0
123	Combining the negative lymph nodes count with the ratio of positive and removed lymph nodes can better predict the postoperative survival in cervical cancer patients. <i>Cancer Cell International</i> , 2013, 13, 6.	1.8	43
124	Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 65-73.	2.0	85
125	Randomized Study of Autologous Cytokine-Induced Killer Cell Immunotherapy in Metastatic Renal Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 1751-1759.	3.2	134
126	Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2125-2133.	2.0	105